2017 Fiscal Year Final Research Report
Do patients taking tacrolimus need to undergo CYP3A5 genotyping along with blood concentration monitoring?
| Project/Area Number |
26460189
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MIURA Masatomo 秋田大学, 医学部, 教授 (30265194)
SATOH Shigeru 秋田大学, 医学部, 教授 (80187195)
TAKAHASHI Naoto 秋田大学, 医学部, 教授 (80344753)
|
|---|
| Research Collaborator |
KAGAYA Hideaki 秋田大学, 病院, 主任
|
|---|
| Project Period (FY) |
2014-04-01 – 2018-03-31
|
| Keywords | タクロリムス / CYP3A5遺伝子多型 / 薬物動態 / 腎移植 / 骨髄移植 / TDM |
|---|
| Outline of Final Research Achievements |
Appropriate tacrolimus (FK) treatment requires higher doses in CYP3A5 expressors (CYP3A5*1/*1 + *1/*3) compared with CYP3A5 nonexpressors (CYP3A5*3/*3), with the former also demonstrating longer times to achieve target trough concentration levels. On the other hand, the concentration of FK in the blood increases significantly in CYP3A5 nonexpressors taking CYP3A inhibitors, such as triazole antifungal agents. Therefore, FK administration should be dose-adjusted based on CYP3A5 genotype prior to initial FK administration, or co-administered with a CYP3A5 inhibitor. Thus, information on the CYP3A5 genotype is useful for therapeutic drug monitoring of FK.
|
| Free Research Field |
臨床薬理学
|
